Established in 2013, Johnson & Johnson’s Office of the Chief Medical Officer (OCMO) is a global team encompassing safety colleagues from across all sectors of Johnson & Johnson. Functionally independent from commercial interests, we focus entirely on the safety of all products across the Johnson & Johnson Family of Companies. Our approach is reinforced by a cutting-edgesingle medical safety standard to which all of our products are held.
The OCMO takes an evidence- and science-based, ethics- and values-driven approach to medical safety—with an emphasis on transparency. This has led to the development of policies and initiatives that keep the needs of patients and consumers at the center of our efforts.
Patients eagerly await new treatments, and some who are seriously ill and have exhausted all other treatment options may benefit from access to a medication before approval for commercial use. Beverly Harrison, Head, Patient Support, Janssen Pharmaceutical Companies of Johnson & Johnson, describes the pathways patients may take to gain access to medicines while still in development.